A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who ...
Study explored safety and efficacy of novel PRRT approach using SSTR antagonist DOTA-LM3 labeled to the alpha-emitting ...
Adding the somatostatin analog lanreotide to the mTOR inhibitor everolimus significantly prolonged progression-free survival in patients with unresectable or recurrent gastroenteropancreatic ...
More than 40,000 people will be told they have liver cancer this year. 30,000 will die from the disease. It’s considered the leading cause of cancer deaths worldwide. Traditional treatments include ...
Symptoms of neuroendocrine tumors (NETs) can vary depending on their location and severity. General symptoms include extreme fatigue, unexplained weight loss, and loss of appetite. NETs are a rare ...
Dr. Kimberly Perez and Dr. Jaydira Del Rivero discuss the new guideline from ASCO on symptom management for well-differentiated GEP-NETs. They share the latest recommendations on managing symptoms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results